JORGE E CORTES to Quinolones
This is a "connection" page, showing publications JORGE E CORTES has written about Quinolones.
Connection Strength
1.364
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.339
-
Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92.
Score: 0.263
-
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome. Curr Hematol Rep. 2004 May; 3(3):157-8.
Score: 0.216
-
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003 Mar 01; 101(5):1692-7.
Score: 0.195
-
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 Jan 15; 14(2):509-14.
Score: 0.070
-
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6.
Score: 0.069
-
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
Score: 0.056
-
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92.
Score: 0.054
-
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 Dec 15; 102(13):4527-34.
Score: 0.052
-
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S30-5.
Score: 0.051